WT1基因突变对急性髓系白血病患者预后的影响
WT1突变型患者展现出独特的共突变谱,常与CEBPA(bZIP)和FLT3-ITD共突变。整体及按2022 ELN风险分层分析均显示WT1突变与OS、RFS、EFS无显著相关性,多因素分析表明WT1非独立预后风险因素。
要点
- WT1突变在AML中发生率9.2%,与CEBPA(bZIP)、FLT3-ITD共突变频率高。
- 整体队列中WT1突变对OS、RFS、EFS无显著影响。
- WT1并非AML独立预后风险因素。
核心结论
- 在本队列中WT1突变与AML不良预后无显著相关性,也非独立预后风险因素。
主要发现
- WT1突变型与野生型患者在临床特征上差异无统计学意义(均P>0.05)。
- WT1突变型患者CEBPA(bZIP)共突变频率为30.1%对15.0%(P<0.001),FLT3-ITD为30.1%对19.8%(P=0.036)。
- WT1突变型患者NPM1共突变频率为11.0%对20.4%(P=0.068),RUNX1::RUNX1T1为4.8%对19.2%(P<0.001)。
- 整体队列和各2022 ELN风险分层中,WT1突变型与野生型患者的OS、RFS、EFS差异均无统计学意义(均P>0.05)。
- WT1和CEBPA(bZIP)共突变患者显示出更差的RFS(P=0.042)和EFS(P=0.017)。
关键数值与推荐
- 多因素Cox回归分析显示WT1不是影响预后的独立因素:OS P=0.209,HR=0.796,95%CI 0.558~1.137;RFS P=0.390,HR=1.149,95%CI 0.837~1.579;EFS P=0.180,HR=1.192,95%CI 0.922~1.542。
临床怎么用
- WT1突变状态不宜单独作为AML预后分层或治疗决策的依据。
- 对于WT1与CEBPA(bZIP)共突变的患者,需关注其RFS和EFS可能更差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the prognostic impact of WT1 mutations in patients with acute myeloid leukemia (AML) . Methods: This was a retrospective cohort study. A total of 1 583 patients with AML who were admitted to the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, from January 2015 to March 2024 were enrolled in the study, including 1 437 WT1 wild-type patients and 146 (9.2%) carrying WT1 mutations. Clinical characteristics and gene mutation profiles were comprehensively compared between WT1-mutated and wild-type cohorts. Survival analyses were performed on WT1-mutant and WT1 wild-type patients in accordance with the 2022 ELN risk classification and major AML mutation subgroups. The primary outcome measures included overall survival (OS), relapse-free survival (RFS), and event-free survival (EFS) . Results: No statistically significant difference in clinical characteristics was found between WT1-mutant and WT1 wild-type patients (all P>0.05). In addition, WT1-mutant AML displayed a unique genomic alteration profile, which is characterized by high frequencies of CEBPA(bZIP) (30.1% vs 15.0%, P<0.001) and FLT3-ITD (30.1% vs 19.8%, P=0.036), along with a reduced incidence of NPM1 (11.0% vs 20.4%, P=0.068) and RUNX1::RUNX1T1 (4.8% vs 19.2%, P<0.001). Survival analysis of the entire cohort and within the 2022 ELN risk classification revealed no significant differences in OS, RFS, or EFS between WT1-mutated and wild-type groups (all P>0.05). Although WT1 mutations had no significant prognostic impact on different AML subgroups, WT1 mutations were associated with inferior RFS (P=0.042) and EFS (P=0.017) in patients co-mutated with CEBPA(bZIP). Clinical factors, including age, sex, and common AML mutation genes, were incorporated into multivariate Cox regression analyses, which consistently showed that WT1 was not an independent prognostic risk factor (OS: P=0.209, HR=0.796, 95%CI: 0.558-1.137; RFS: P=0.390, HR=1.149, 95%CI: 0.837-1.579; EFS: P=0.180, HR=1.192, 95%CI: 0.922-1.542) . Conclusion: Although WT1 is a common mutation gene in AML, it was not associated with poor prognosis and was not an independent prognostic risk factor in our cohort. 目的: 探究WT1基因突变对急性髓系白血病(AML)患者预后的影响。 方法: 本研究为回顾性队列研究。纳入1 583例2015年1月至2024年3月中国医学科学院血液病医院收治的AML患者,其中WT1野生型患者1 437例,WT1突变型患者146例(9.2%)。分析WT1突变型患者和野生型患者的临床特征和基因突变谱,根据2022年欧洲白血病网(ELN)风险分层和AML主要突变亚型分组对WT1突变型和野生型患者进行生存分析,观察总生存(OS)期、无复发生存(RFS)期和无事件生存(EFS)期。 结果: WT1突变型和野生型患者在临床特征上差异无统计学意义(均P>0.05)。WT1突变型患者展示出独特的基因突变谱,常与CEBPA(bZIP)(30.1%对15.0%,P<0.001)和FLT3-ITD(30.1%对19.8%,P=0.036)共突变,较少与NPM1(11.0%对20.4%, P=0.068)和RUNX1::RUNX1T1(4.8%对19.2%, P<0.001)发生共突变。生存分析显示,在整体队列和各2022年ELN风险分层患者中,WT1突变型和野生型两组患者的OS、RFS和EFS差异均无统计学意义(均P>0.05)。WT1突变对各个AML突变亚型的预后均无明显影响,但是WT1和CEBPA(bZIP)共突变患者显示出更差的RFS(P=0.042)和EFS(P=0.017)。将年龄、性别、AML常见基因突变等临床因素纳入多因素Cox回归分析中,结果显示WT1不是影响预后的独立因素(OS:P=0.209,HR=0.796,95%CI:0.558~1.137;RFS:P=0.390,HR=1.149,95%CI:0.837~1.579;EFS:P=0.180,HR=1.192,95%CI:0.922~1.542)。 结论: 尽管WT1是AML的常见突变基因,但在本队列患者中,其存在与不良预后无显著相关性,也非独立的预后风险因素。.
引用
- Zeng Y, Hui Y, Yan L, et al. [Prognostic impact of WT1 mutations in patients with acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42409732. doi:10.3760/cma.j.cn121090-20251222-00608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。